Testosterone often changes with age, but there is no single age chart that decides whether a man has testosterone deficiency. A useful interpretation separates population ranges from clinical thresholds and considers symptoms, testing conditions, SHBG and the reason for the result.
A testosterone result needs more context than an age bracket and a coloured bar. Age affects hormone patterns, but so do sleep, body composition, illness, medicines, testing time, food intake, sex hormone-binding globulin and laboratory method. Two men of the same age can therefore have different results without either result proving disease.
Interpretation depends on whether the result was collected correctly, whether it is persistent, whether the man has a compatible clinical pattern and what might explain it. An age-based population chart describes a group; it cannot diagnose the person reading it.
In adult men, total testosterone tends to be higher in early adulthood and may decline with age, while sex hormone-binding globulin often rises and free testosterone may fall more quickly. That trend is real, but it is not a universal timetable and does not create a separate do-it-yourself treatment threshold for each birthday.
A widely cited harmonised study found a total-testosterone reference interval of 264-916 ng/dL, approximately 9.2-31.8 nmol/L, in healthy non-obese men aged 19-39. That is a research reference interval for a selected population measured with standardised methods. It is not an "optimal" target, and it should not be applied uncritically to every laboratory or older man.
For UK clinical assessment, the more relevant framework uses compatible symptoms, correctly collected repeat tests and cause-finding. The joint Society for Endocrinology and Association for Laboratory Medicine position statement treats two morning, fasting results below 8 nmol/L as likely hypogonadism in a symptomatic man; 8-12 nmol/L as a borderline zone; and a correctly collected result above 12 nmol/L as not usually consistent with hypogonadism. These are action cut-offs for assessment, not age-specific reference ranges or automatic prescribing rules.
Several different concepts are often compressed into the word "normal".
A reference interval describes the distribution of results in a selected reference population, commonly the central 95%. It depends on who was included, how samples were collected and which assay was used. Being just outside an interval does not by itself prove illness, and being inside it does not explain symptoms.
An action threshold helps a clinician decide when a result is likely, borderline or unlikely to represent hypogonadism in the right clinical context. It is not the same as a population average or a promise that treatment will help everyone below it.
An average describes the centre of a group. Half the measured values may sit above it and half below it. Calling the average "optimal" turns a descriptive statistic into a treatment claim it was not designed to support.
A treatment target applies only after a sound diagnosis and depends on the formulation, sampling time, symptoms and safety monitoring. It should not be used to justify treatment in a man whose natural result is within a physiological range and who does not have hypogonadism.
| Age or life stage | What the evidence can tell us | Important limitation |
|---|---|---|
| Childhood and puberty | Testosterone changes substantially with pubertal stage and must be interpreted using paediatric methods and reference intervals | Adult ranges and adult TRT thresholds do not apply |
| 19-39 years | A harmonised study of healthy non-obese European and US men reported 264-916 ng/dL, about 9.2-31.8 nmol/L, as the 2.5th-97.5th percentile interval | This selected research population is not a universal UK diagnostic range or an "optimal" band |
| 20-44 years | A US study proposed age-specific low-testosterone cut-offs for younger men, from about 409 ng/dL at 20-24 to 350 ng/dL at 40-44 | These proposed cut-offs are not a replacement for current UK diagnostic guidance, local assays, symptoms or repeat testing |
| 40-79 years | European data show gradual average change, with free testosterone declining faster than total testosterone as SHBG rises | A group trend cannot distinguish healthy ageing from obesity, illness, medicine effects or organic hypogonadism in an individual |
| Later life | Lower results and comorbidity become more common, but marked deficiency may still reflect testicular or pituitary disease | Age should not be used to dismiss a well-founded diagnosis or to medicalise nonspecific symptoms automatically |
The purpose of this table is to show the strength and boundary of each type of evidence. It is not a calculator for self-diagnosis.
The familiar "1% per year" phrase is a rough population summary, not a biological countdown for every man. The current European Association of Urology guideline cites European Male Ageing Study estimates of an average 0.4% annual decline in total testosterone and a 1.3% annual decline in free testosterone. The difference is partly explained by rising SHBG.
Those averages combine men with different health trajectories. Weight gain, insulin resistance, chronic disease, medicines, sleep problems and reduced physical activity can contribute to the apparent age relationship. Longitudinal research suggests that accumulating illness and obesity may account for much of the fall often attributed to age alone.
One man may remain stable over years. Another may have a temporary fall during illness or under-fuelling. A third may develop true primary testicular failure or a pituitary disorder. Age is relevant background, not the diagnosis.
Not automatically. Older age makes lower total and free testosterone more common, but it does not make clinically important hypogonadism harmless or inevitable. Conversely, an older man with fatigue and a low-normal result does not automatically benefit from TRT.
The decision still turns on:
The label "age-related low T" should never replace a proper investigation.
For morning, fasting samples in symptomatic adult men, the joint UK position statement provides a practical interpretation:
| Total testosterone result | General clinical interpretation |
|---|---|
| Below 8 nmol/L on two separate tests | Hypogonadism is likely, subject to clinical assessment and investigation of the cause |
| 8-12 nmol/L | Borderline: interpret symptoms, SHBG, calculated free testosterone where indicated, assay context and related hormones |
| Above 12 nmol/L | Not usually consistent with hypogonadism; one correctly collected result above this level will usually exclude it |
The EAU uses 12 nmol/L as a clinical threshold for symptomatic late-onset hypogonadism and recommends repeating a result below that level before treatment. BSSM guidance uses a related framework but includes treatment recommendations that should be applied by an appropriately qualified clinician, not copied into a consumer eligibility quiz.
Different guidance can use different wording because reference intervals, diagnostic thresholds and treatment thresholds answer different questions. Any threshold should be identified and explained rather than presented as a single settled number.
Testosterone assays are not perfectly interchangeable. Calibration, platform, sample handling and the population used to build the reference interval can all affect the reported range. The harmonisation study of 9,054 men found that assay differences explained a substantial part of the variation between cohorts before their results were standardised.
A result should be interpreted using the reporting laboratory's method and reference information. Converting nmol/L to ng/dL changes the unit, not the assay or the clinical meaning.
For total testosterone, an approximate conversion is:
A unit converter can prevent transcription mistakes, but it cannot determine whether treatment is appropriate.
Most circulating testosterone is bound to SHBG or albumin. Only a small fraction is unbound. As SHBG often rises with age, total testosterone can appear relatively preserved while calculated free testosterone falls.
That does not mean free testosterone should replace total testosterone in every case. The UK joint position statement says calculated free testosterone usually adds little when SHBG is within range. It may be helpful when SHBG is high, because total testosterone can look reassuring despite a low calculated free fraction, or when SHBG is low, because total testosterone can look low despite an adequate free fraction.
The laboratory method matters. Equilibrium dialysis followed by mass spectrometry is considered the reference method for free testosterone but is not routinely available in UK practice. Many direct free-testosterone immunoassays are inaccurate. A calculated result is an estimate derived from total testosterone, SHBG and usually albumin.
Interpretation should account for factors that can suppress testosterone temporarily or persistently:
Some of these factors change SHBG as well as testosterone. The pattern across total testosterone, SHBG, calculated free testosterone, LH and FSH is often more informative than one number viewed alone.
A high result is not automatically a sign of better health. It may reflect a high SHBG level, prescribed testosterone sampled at a particular point in the dosing cycle, non-medical androgen use, a supplement containing undeclared hormones, assay interference or, less commonly, an underlying condition.
Men using prescribed TRT should follow formulation-specific sampling instructions. Comparing a post-dose peak with an untreated morning reference interval can create a false impression. Unexpectedly high natural or treated results should be reviewed with the prescriber rather than "balanced" with another medicine or supplement.
The best outcome may be treatment of an underlying condition, specialist investigation, monitored testosterone treatment, a fertility-preserving plan or reassurance. A careful service should be able to recommend any of those paths.
On average, yes. SHBG often rises with age, and European data show a faster decline in free than total testosterone. The individual result still depends on health, body composition, assay and clinical context.
No. A calculator can convert units or display population data. It cannot verify sample quality, symptoms, SHBG, repeatability, cause, fertility implications or treatment safety.
No. Most men do not experience a universal "male menopause," and TRT is not routine anti-ageing treatment. It is considered when a man has compatible symptoms, confirmed biochemical deficiency and a cause for which treatment is appropriate.
